Abstract O116 – Table 1. Prevalence and incremental cost estimates for acute and chronic non‐HIV related comorbidities included in the final model
| Comorbidities | Prevalence | Incremental cost (€) | 95% CI of cost (€) (lower) | 95% CI of cost (€) (upper) | p value |
|---|---|---|---|---|---|
| Intercept | 4766 | 4460 | 5093 | ||
| Gender, being female | 17.4% | ‐1,678 | ‐1929 | ‐1327 | <0.001 |
| Acute conditions | |||||
| Acute cardiovascular disease | 12.7% | 4791 | 3165 | 6884 | <0.001 |
| Acute hepatitis C | 2.4% | 14,525 | 8618 | 23,360 | <0.001 |
| Acute renal disease | 1.3% | 7366 | 2742 | 15,340 | <0.001 |
| Bone fractures due to osteoporosis | 9.0% | 3511 | 2020 | 5481 | <0.001 |
| Chronic conditions | |||||
| Chronic hepatitis C | 8.5% | 16,023 | 11,771 | 21,535 | <0.001 |
| Diabetes mellitus type 2 | 8.3% | 2581 | 1214 | 4421 | <0.001 |
| Dyslipidaemia | 23.5% | ‐867 | ‐1250 | ‐356 | 0.002 |
| Moderate or severe liver disease | 0.6% | 0.438 | |||
ART = antiretroviral treatment. Evaluation of the model appropriateness; AIC = 40,587, Box Cox λ = 0, Park test estimate = 2.24, scaled deviance/df =1.2.